svg-arrow-next svg-arrow-prev
×

Order online: 0917-565-3700/ 0998-530-3700

sidebar

Lixiana 60mg Tab

(No reviews) Write a Review
₱150.00

SKU:
030504


Note: Uploaded prescription slip is subject to validation by our Pharmacist.

file types are bmp, gif, jpg, jpeg, jpe, jif, jfif, jfi, png, wbmp, xbm, tiff

Lixiana 60mg Tab

₱150.00

Lixiana 60mg Tab

₱150.00

file types are bmp, gif, jpg, jpeg, jpe, jif, jfif, jfi, png, wbmp, xbm, tiff

Generic Name Edoxaban (as tosilate)
Strength 60 mg
Indication/Usage Indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age > 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
Indicated in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults.
Dosage and Administration Prevention of stroke and systemic embolism: The recommended dose is 60 mg edoxaban once daily. Therapy with edoxaban in NVAF patients should be contined long-term.
Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTE): The recommended dose is 60 mg edoxaban once daily following initial use of parenteral anticoagulant for at least 5 days. Edoxaban and initial parenteral anticoagulant should not be administered simultaneously. For more information, please refer to package insert.
Warning and Precautions Edoxaban 15 mg is not indicated as monotherapy, as it may result in decreased efficacy. It is only indicated in the process of switching from Edoxaban 30 mg to VKA together with an appropriate VKA dose.
Haemorrhagic Risk: Edoxaban is recommended to be used with caution in patients with increased risk of bleeding. Edoxaban administration should be discontinued if severe hemorrhage occurs.
Elderly: The co-administration of Edoxaban with ASA in elderly patients should be used cautiously because  of a potentially higher bleeding risk.
Renal impairment: In patients with end stage renal disease or on dialysis, edoxaban is not recommended.
Renal function in NVAF: Edoxaban should be used in patients with NVAF and high CrCl only after a careful evaluation of the individual thromboembolic and bleeding risk.
Hepatic impairment: Edoxaban is not recommended in patiemts with severe hepatic impairment.
Discontinuation of surgery and other interventions
Prosthetic heart valves and moderate to severe mitral stenosis
Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy
Patients with active cancer
Patients with antiphospholipid syndrome
Laboratory coagulation parameters
Drug Interaction Edoxaban 30 mg once daily must be administered during concomitant use with the ff P-gp inhibitors: Ciclosporin, Dronedarone, Erythromycin, Ketoconazole
Edoxaban 60 mg once daily is recommended during concomitant use with the ff P-gp inhibitors: Quinidine, Verapamil, Amiodarone
P-gp inducers: rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's wort
P-gp substrates: Digoxin
Anticoagulants, ASA, Platelet inhibitors, NSAIDs, SSRIs/SNRIs
Requires Prescription? (Yes or No) Yes

 

Related Products

Be a member